PharmAbcine Announced the Preclinical Data of PMC-403 for Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. Clarkson Disease)
Shots:
- The Preclinical study evaluating PMC-403 efficacy on Idiopathic Systemic Capillary Leak Syndrome (ISCLS) models showed reduced vascular leakage associated with ISCLS
- The result of the study demonstrated effectiveness in improving survival and reducing vascular leakage in the histamine-induced ISCLS mouse model. The investigation expanded to include the treatment of influenza-exposed mice, which showed encouraging outcomes in lowering vascular leakage
- PMC-403 is an antibody targeting the Tie2 receptor with a mode of action that restores the leaky, diseased blood vessels by activating the Tie2 receptor, additionally it received ODD from the US FDA
Ref: PR Newswire | Image: PharmAbcine
Related News:- Pliant Therapeutics Reports an Initiation of P-IIb Trial (BEACON-IPF) for Bexotegrast to Treat Idiopathic Pulmonary Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
